James C. Momtazee - Oct 16, 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for James C Momtazee
Stock symbol
ROIV
Transactions as of
Oct 16, 2023
Transactions value $
-$7,076
Form type
4
Date filed
10/18/2023, 09:30 PM
Previous filing
Sep 20, 2023
Next filing
Jan 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Award $0 +1.59K +2.16% $0.00 75.5K Oct 16, 2022 Direct F1, F2
transaction ROIV Common Shares Other -$7.08K -687 -0.91% $10.30 74.8K Oct 17, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects an award of restricted stock covering Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date.
F2 The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities.
F3 Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering Common Shares. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.